Skip to content

Cancer Health Center

Font Size

Chronic Myelogenous Leukemia Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (08 / 02 / 2013)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Chronic Myelogenous Leukemia

Recommended Related to Cancer

What is prevention?

Cancer prevention is action taken to lower the chance of getting cancer. By preventing cancer, the number of new cases of cancer in a group or population is lowered. Hopefully, this will lower the number of deaths caused by cancer. To prevent new cancers from starting, scientists look at risk factors and protective factors. Anything that increases your chance of developing cancer is called a cancer risk factor; anything that decreases your chance of developing cancer is called a cancer protective...

Read the What is prevention? article > >

Added Jabbour et al. as reference 10.

Stage Information for Chronic Myelogenous Leukemia

Added Jabbour et al. as reference 1.

Added Fabarius et al. as reference 4.

Treatment Option Overview

Added Jabbour et al. as reference 1.

Revised text to state that in a randomized, prospective study of 846 patients comparing nilotinib with imatinib, the rate of major molecular response at 24 months was 71% and 67% for two-dose schedules of nilotinib and 44% for imatinib. Also added that progression to accelerated-phase chronic myelogenous leukemia (CML) or blast-crisis occurred in 17 patients on imatinib, but this progression only occurred in two patients and five patients, respectively, on two-dose schedules of nilotinib (cited 2011 Kantarjian et al. as reference 7).

Revised text to state that the rate of major molecular response at 24 months was 64% for dasatinib and 46% for imatinib. Also added that progression to accelerated-phase CML or blast-crisis phase occurred in 13 patients on imatinib and in six patients on dasatinib, which is not statistically different (cited 2012 Kantarjian et al. as reference 8 and level of evidence 1iiDiv).

Chronic-Phase Chronic Myelogenous Leukemia

Revised text to state that in a randomized, prospective study of 846 patients comparing nilotinib with imatinib, the rate of major molecular response at 24 months was 71% and 67% for two-dose schedules of nilotinib and 44% for imatinib. Also added that progression to accelerated-phase CML or blast crisis occurred in 17 patients on imatinib, but this progression only occurred in two patients and five patients, respectively, on two-dose schedules of nilotinib (cited 2011 Kantarjian et al. as reference 7).

Revised text to state that the rate of major molecular response at 24 months was 64% for dasatinib and 46% for imatinib. Also added that progression to accelerated-phase CML or blast-crisis phase occurred in 13 patients on imatinib and in six patients on dasatinib, which is not statistically different (cited 2012 Kantarjian et al. as reference 8 and level of evidence 1iiDiv).

    1|2
    Next Article:

    Today on WebMD

    Colorectal cancer cells
    A common one in both men and women.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Real Cancer Perspectives
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article